Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEAPROSTIL + tamsulosin
- Development stage
- Preclinical
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PEAPROSTIL + tamsulosin is a combination therapy consisting of PEAPROSTIL 600, a food supplement containing Palmitoylethanolamide (PEA) and Serenoa Repens (saw palmetto), and tamsulosin, an alpha-1A and alpha-1B adrenergic receptor antagonist. This combination is being investigated for the treatment of benign prostatic hyperplasia (BPH) symptoms, with the goal of reducing lower urinary tract symptoms (LUTS) through complementary mechanisms of action.
02
Targets
ADRA1A (α1A)ADRA1D (α1D)
Beyond the preview
Go deeper on PEAPROSTIL + tamsulosin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEAPROSTIL + tamsulosin.